UnknownNCT04259255
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tanabe Pharma America, Inc.
- Principal Investigator
- James Berry, MD, MPHMassachusetts General Hospital
- Intervention
- Edaravone (Radicava®/Radicava ORS®)(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (20)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- UCLA Als Clinic, Los Angeles, California, United States
- UC Davis Health, Sacramento, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Colorado, Denver, Colorado, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Jacksonville -Neurology Research Department, Jacksonville, Florida, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mercy Health, Grand Rapids, Michigan, United States
- Neurology Associates, P.C., Lincoln, Nebraska, United States
- Las Vegas Clinic, Las Vegas, Nevada, United States
- OhioHealth, Columbus, Ohio, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Massachusetts General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04259255 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)